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Abstract
 
Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma re-
quires the disruption of either of two immunoregulatory mechanisms that control autoreactive
T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the
 
CD25
 
 
 
 regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25
 
 
 
Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with
 
the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-
 
related protein 2
 
180–188
 
–specific CTLs detected in the periphery. Furthermore, tumor rejection
is dependent on the CD8
 
 
 
 T cell subset. Our data demonstrate that the CTL response against
melanoma antigens is an important component of the therapeutic antitumor response and that
the reactivity of these CTLs can be augmented through interference with immunoregulatory
mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25
 
 
 
 Treg
cells indicates that CD25
 
 
 
 Treg cells and CTLA-4 signaling represent two alternative path-
ways for suppression of autoreactive T cell immunity. Simultaneous intervention with both
regulatory mechanisms is therefore a promising concept for the induction of therapeutic anti-
tumor immunity.
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Introduction
 
T cell–mediated immunotherapy represents a promising
treatment for human malignancies. In cancer patients, the
absence of efficient tumor-specific immunity can be related
to inadequate APC function or to T cell tolerance/igno-
rance towards tumor antigens (1). Nevertheless, extensive
studies of melanoma patients revealed that CTLs against a
number of melanocyte/melanoma-specific antigens (e.g.,
 
gp100, MART-1, and tyrosinase-related protein [TRP]
 
*
 
-2)
can be retrieved from the blood of such patients (2–4). Ini-
tiation of T cell responses requires stimulation of the T cell
receptor via its peptide/MHC ligand on the APCs, as well
as costimulatory signals (5). The major costimulatory mole-
cule on T cells is generally thought to be CD28. CTL–asso-
ciated antigen (CTLA)-4, which shares its ligands (CD80
and CD86) with CD28, downregulates T cell responsive-
ness, thereby raising the threshold for T cell activation (6–
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8). By this mechanism CTLA-4 signaling can, amongst oth-
ers, prevent the initiation of autoreactive T cell responses.
Besides CTLA-4, CD4
 
 
 
 T cells have been associated
with suppression of T cell responses. North et al
 
. 
 
had al-
ready demonstrated that CD4
 
 
 
 T cells from tumor-bearing
mice were capable of inhibiting the effect of adoptive T cell
therapy (9). Also, recent reports have shown that several
subsets of regulatory T (Treg) cells are involved in control-
ling autoreactive lymphocytes. In particular, Sakaguchi and
colleagues (10) showed that Treg cells with strong suppres-
sive capacities are defined by the expression of the CD25
marker (the IL-2R 
 
 
 
 chain). Elimination of CD25
 
 
 
 T cells
results in the development of autoimmune diseases in ro-
dents, whereas administration of such Treg cells prevents
development of the autoimmune disease (10–13). In vitro,
CD4
 
 
 
CD25
 
 
 
 T cells are nonproliferative to antigenic
stimulation, but strongly inhibit the activation of other
CD4
 
 
 
 or CD8
 
 
 
 T cells (14–17). The mode of action of
these Treg cells is currently under intensive investigation.
We have shown previously that disruption of negative
regulatory mechanisms, through blockade of CTLA-4, can
unleash therapeutic T cell immunity against the poorly im-
munogenic melanoma B16-BL6 (18). Effective treatment of
B16-challenged mice was achieved through administration
of a combination of a GM-CSF–producing tumor cell vac-
cine and CTLA-4–blocking antibodies. Tumor rejection
was accompanied by skin depigmentation, suggesting that
autoreactive immune responses are involved in this process.
Furthermore, therapeutic efficacy in this setting was found
to depend on the CD8
 
 
 
, but not the CD4
 
 
 
 T cell subset,
making this experimental system a highly relevant model for
CTL-mediated immunotherapy of human melanoma.
In this study we show that the therapeutic efficacy of the
B16-GM-CSF tumor cell vaccine was equally potentiated if
combined with prior in vivo depletion of CD25
 
 
 
 T cells,
instead of CTLA-4 blockade. Moreover, combination of
CD25 depletion and CTLA-4 blockade resulted in an even
more potent effect of the antitumor treatment. Increased
efficacy of treatment was associated with increased frequen-
cies of CTLs specific for the melanocyte/melanoma differ-
entiation antigen TRP-2, as well as by more profound skin
depigmentation. In the absence of CD25
 
 
 
 Treg cells,
CTLA-4 blockade enhanced the induction of effector
CTLs in vitro as well as in vivo. Our data argue that
CTLA-4 blockade and CD25
 
 
 
 T cell depletion affect alter-
native regulatory mechanisms. The combination of these
vaccination strategies strongly enhances autoreactive cellu-
lar immunity leading to effective immunotherapy of cancer.
 
Materials and Methods
 
Cell Lines and Mice.
 
B16-BL6 (obtained from I Fidler, MD
Anderson Cancer Center, Houston, TX), GM-CSF–producing
B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18),
9H10 (19), and PC61 (American Type Culture Collection) were
cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1
U/ml penicillin, 1 
 
 
 
g/ml streptomycin, 2 
 
 
 
M 
 
L
 
-glutamine, 20
 
 
 
M
 
  
 
-mercaptoethanol (complete medium), and 4% FCS. GM-
 
CSF production by BL6/GME and BL6/GM18 was confirmed
in vitro during the course of the vaccination experiments. T cells
were cultured in complete medium supplemented with 8% FCS
and 10 Cetus U IL-2 per milliliter.
C57BL/6 female mice were obtained from IFFA Credo,
C57BL/6 Nude (
 
nu/nu
 
) female mice were obtained from Bom-
holtgard and were maintained and treated in accordance with the
national guidelines for animal care. Mice were treated and used
for tumor experiments when 8–12 wk old.
 
Antibodies and Peptides.
 
Anti–murine CTLA-4 antibody
9H10 (hamster) and anti–murine CD25 antibody PC61 (rat)
were purified using a protein G agarose column (Roche). For de-
pletions, GK1.5 (anti-CD4), 2.43 (anti-CD8) were purified in
our laboratory from hybridoma culture supernatant using protein
free hybridoma medium (Life Technologies) and a capillary dia-
lyzer (Fresenius Medical Care, St. Wendel, Germany). Rat IgG
was obtained from Sigma-Aldrich. Anti–CD4-APC, anti–CD8b-
FITC, anti–CD8a-APC, and anti–CD25-FITC (7D4) were ob-
tained from BD PharMingen and were used to confirm deple-
tions of the relevant cell populations, anti–CD25-PE (PC61) was
obtained from Beckman Coulter. We tested GM-CSF produc-
tion by lines GME and GM18 by an ELISA using commercially
available antibodies to murine GM-CSF (BD PharMingen).
H-2K
 
b
 
 tetramers were produced as described previously (20, 21)
and stored frozen in Tris-buffered saline/16% glycerol/0.5%
BSA. Peptides were produced by using standard F-moc chemis-
try. The purity was checked by HPLC and fractions were con-
firmed to contain 
 
 
 
95% of the expected sequence.
 
Treatment of B16-BL6 Tumors.
 
Mice were challenged subcu-
taneously on the right flank with 2.5 
 
  
 
10
 
3
 
 (or the amount indi-
cated) B16-BL6 tumor cells in 200 
 
 
 
l PBS-0.1% BSA. At the
same day, treatment was initiated by injecting 10
 
6
 
 irradiated
(16,000 rad) GM-CSF–producing B16 cells (clones GME and
GM18 in a 1:1 mixture) subcutaneously into the left flank, and re-
peated 3 and 6 d later. Simultaneously with the cellular vaccina-
tions, the mice were injected (on days 0, 3, and 6) intraperito-
neally with 200 
 
 
 
g anti–CTLA-4 antibody (19) in 200 
 
 
 
l PBS.
Tumor growth was scored by measuring perpendicular diameters.
Mice were killed when the tumors displayed ulceration or reached
a size of 150 mm
 
2
 
. Depletion of CD4
 
 
 
 or CD8
 
 
 
 T cells was ac-
complished by injection of the relevant antibodies (100 
 
 
 
g intra-
peritoneally) on days 
 
 
 
1, 0, 7, 14, and 21 (day of tumor challenge
is referred to as day 0). Depletions of CD25
 
 
 
 T cells were per-
formed by intraperitoneal injection of 400 
 
 
 
g PC61 as described
previously (22) at day 
 
 
 
4. Depletions were confirmed by flow cy-
tometry using noncrossreactive antibodies. Statistical analysis was
performed using SPSS data analysis software (SPSS Inc.).
 
Flow Cytometry and IFN-
 
 
 
 Release Assays.
 
Analysis of cell
surface markers on blood lymphocytes was performed using a
FACScalibur™ (Becton Dickinson) and CELLQuest™ software.
Blood (50–100 
 
 
 
l) was collected in heparin-coated tubes and
erythrocytes were lysed using standard laboratory protocols. The
remaining lymphocytes were washed and incubated with the in-
dicated antibodies/tetramers in PBS/1%BSA for 20 min at room
temperature. After two washes with PBS, FACS
 
®
 
 analysis was
performed with the cells in PBS/1%BSA/1 
 
 
 
g/ml propidium io-
dide. Propidium iodide-negative cells were gated for the lym-
phocyte population and analyzed. For intracellular IFN-
 
 
 
 cyto-
kine staining, vaccine draining lymph nodes were isolated and
single cell suspensions were stimulated for 5 h with TRP-2
 
180–188
 
peptide or irrelevant (E1A
 
234–243
 
) peptide at a concentration of 5
 
 
 
g/ml in medium containing Brefeldin A. Cells were then fixed
in paraformaldehyde and incubated with PE-conjugated anti– 
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IFN-
 
 
 
 and APC-conjugated anti-CD8 (BD PharMingen). The
samples were analyzed on a FACScalibur™. For IFN-
 
 
 
 release
assays, splenocytes were restimulated in vitro with 10
 
5
 
 irradiated
(16,000 rad) B16/B7.1 per 10
 
6
 
 splenocytes in IL-2 (10 Cetus U/ml)
supplemented culture medium. After 7 d, splenocytes were
collected and dead cells removed after a Ficol-Hypaque gradient.
Splenocytes (10
 
5
 
 cells per well) were stimulated with target cells
(2 
 
 
 
10
 
4
 
 cells per well) in 96-well round-bottomed plate. After
24 h, supernatant was tested for the presence of IFN-
 
 
 
 by sand-
wich ELISA (BD PharMingen). As target cells we used peptide-
pulsed naive irradiated splenocytes. For peptide pulsing, we incu-
bated 10
 
6
 
 naive splenocytes for 1 h in culture medium containing
25 
 
 
 
g/ml peptide. Unbound peptide was washed away by three
washes in culture medium. Specific IFN-
 
 
 
 release was calculated
as: IFN-
 
  
 
release in response to TRP-2
 
180–188
 
 loaded spleno-
cytes 
 
 
 
 IFN-
 
 
 
 release in response to E1A
 
234–243
 
 loaded splenocytes.
 
In Vitro Priming Assay.
 
CD25-depleted naive splenocytes
were loaded with TRP-2
 
180–188
 
 peptide, irradiated, and used as
stimulatory cells in an in vitro priming assay. Per well of a 24-
well plate, 10
 
6
 
 CD25-depleted naive splenocytes were incubated
with 5 
 
  
 
10
 
5
 
 stimulatory cells in complete medium containing
10 Cetus U of IL-2 per milliliter (and, if indicated, 50
 
  
 
g/ml
CTLA-4–blocking antibody [9H10]). After 3 d, cells were iso-
lated by Ficoll flotation and 4 d later analyzed for specific IFN-
 
 
 
release in response to TRP-2 peptide or irrelevant peptide. Spe-
cific IFN-
 
 
 
 release was calculated as described previously.
 
Depigmentation Studies.
 
Mice were scored for skin depigmen-
tation 
 
 
 
100 d after vaccination. Depigmentation was scored ac-
cording to the presence of depigmented areas on the vaccination
site (1 point), tumor site (1 point), or elsewhere (1 point), render-
ing scores from 0 to 3. Depigmented areas were scored positive
 
when 
 
 
 
25 mm
 
2
 
 and containing
 
  
 
50% depigmented hairs. Scor-
ing was performed in a blinded fashion.
 
Results
 
Depletion of CD4
 
 
 
 or CD25
 
 
 
 T Cells Enhances Efficacy of
Antitumor Treatment.
 
B16-BL6, which was originally se-
lected for its invasiveness (23), is a poorly immunogenic
but highly tumorigenic murine melanoma cell line. Al-
though prophylactic vaccination can generally prevent B16
tumor outgrowth (24–28), vaccination after tumor chal-
lenge is less effective. We have shown previously (18) that
the combination of a GM-CSF–producing tumor cell vac-
cine and CTLA-4–blocking antibodies can be exploited
successfully to treat B16-BL6 tumors. We demonstrated
that antitumor treatment is accompanied by autoimmune
skin depigmentation and that the mechanism of the tumor
rejection is dependent on CD8
 
 
 
 CTLs, whereas CD4
 
 
 
 T
cells are not required. Interestingly, we consistently ob-
served a significant increase in the therapeutic efficacy of
the vaccination if the mice were depleted of their CD4
 
 
 
 T
cells (Fig. 1). In accordance with this, Nagai et al
 
.
 
 (29)
recently reported enhanced tumor rejection and depig-
mentation after CD4
 
 
 
 T cell depletion in a study using
IL-12–producing B16 cells. These results suggest a possible
inhibitory role for CD4
 
 
 
 Treg cells in the control of au-
toreactive CTLs. Recent reports (16, 30) have associated
the surface marker CD25 with Treg cells. Since the antitu-
mor response in our model involves CTL-dependent
autoimmune depigmentation, we investigated whether
CD25
 
 
 
 Treg cells were responsible for limiting the magni-
tude and/or efficacy of the (autoreactive) immune response
in this therapeutic setting. CD4
 
 
 
CD25
 
 
 
 T cells make up
Figure 1. CD4  T cell depletion before vaccination enhances efficacy
of B16 treatment. Survival data of mice challenged subcutaneously (day 0)
with 5   103 B16-BL6 tumor cells. Mice received either no treatment
(n   25,  ) or B16-GM-CSF tumor cell vaccine in combination with
anti–CTLA-4–blocking Ab on days 0, 3, and 6. The vaccinated mice
were divided over three groups that received the following Ab on days
 1, 0, 7, and 14: depleting anti-CD8 Ab (n   25,  ), depleting anti-
CD4 Ab (n   25, ×), or isotype matched control Ab (n   25,  ). Details
on experimental procedure and Ab are described in Materials and Meth-
ods. The graph indicates the percentage of surviving mice over time.
Significant (P   0.04, log rank test) difference was found between B16-
GM-CSF and anti–CTLA-4–treated mice injected with control antibody
( ) and mice injected with CD4-depleting Ab (×).
Figure 2. Characterization of blood lymphocytes in CD25-depleted
C57BL/6 mice. (A and B) Blood lymphocytes from a naive (A) or a
CD25-depleted (B) mouse were stained 21 d after CD25 depletion, with
APC-conjugated anti-CD4 and PE-conjugated anti-CD25. Numbers in
the upper right quadrant indicate the percentage of CD25 /CD4  T cells
of total CD4  T cells. (C and D) Blood lymphocytes from a naive (C) or a
CD25-depleted/B16-GM-CSF/anti–CTLA-4 vaccinated mouse (D)
were stained on day 17 after vaccination for the presence of TRP-2180-188–
specific CD8  T cells using an APC-conjugated TRP-2180–188 Kb-tetramer
and anti–CD8-FITC. Numbers in the upper right quadrant indicate the
percentage of TRP-2180–188–specific CD8  T cells of total CD8  T cells.
Representative stainings of three independent experiments are shown.826 Suppression of CTL Responses through CTLA-4 and Treg Cells
 5% of the total peripheral CD4  T cell population in na-
ive C57BL/6 mice (Fig. 2 A). Mice that received a single
dose of 0.4 mg of CD25-depleting antibody showed ap-
proximately a tenfold reduction in the CD4 CD25  T cell
population (Fig. 2 B), comparable to what was previously
reported by others (22). CD25 depletion before tumor
challenge resulted in a small but reproducible delay in tu-
mor outgrowth compared with naive mice (Fig. 3 A), indi-
cating that this intervention improved the antitumor im-
mune response of these mice even in the absence of
vaccination. Combination of the GM-CSF–producing vac-
cine with CD25  T cell depletion was equally effective in
preventing tumor outgrowth as combination of the vaccine
with CTLA-4 blockade (Fig. 3 A). This indicated that both
of these immunomodulation strategies improved the effi-
cacy of the GM-CSF–producing vaccine. Importantly,
combination of this vaccine with both CTLA-4 blockade
and CD25 depletion resulted in a further increase of treat-
ment efficacy in that all mice were capable of rejecting the
B16 tumor (Fig. 3 A).
To more extensively probe the potency of CD25  T cell
depletion in antitumor treatment, mice were challenged
with the double number of highly malignant B16-BL6 tu-
mor cells (5   103 cells) compared with the experiments
described in Figs. 1 and 3 A. In this particular setting, mice
receiving the combination of GM-CSF–producing B16
vaccine plus CTLA-4 blockade experienced a delay in tu-
mor outgrowth but failed to reject the tumor, due to more
rapid tumor outgrowth (Fig. 3 B). Interestingly, when the
GM-CSF–producing B16 vaccine plus CTLA-4 blockade
was applied to mice that had undergone prior CD25 deple-
tion, most mice did reject their tumor (6/9 survival). This
illustrates even more dramatically the strong immunoregu-
latory action of the CD25  T cell subset in preventing the
development of an effective antitumor immunity.
The same conclusion pertains to the role of this T cell
subset in immune responses causing skin depigmentation.
CD25-depleted, vaccinated animals experienced more pro-
nounced and widespread autoimmune skin depigmentation
than mice receiving the GM-CSF–producing B16 vaccine
plus CTLA-4 blockade alone (Fig. 4). Taken together, our
data show that disruption of immunoregulatory processes
Figure 3. CD25  T cell depletion before
vaccination enhances efficacy of treatment. (A)
Survival data of mice challenged subcutaneously
with 2.5   103 B16-BL6 tumor cells. Mice re-
ceived either no treatment (n   6,  ), or de-
pleting anti-CD25 on day  4 (n   6,  ) or
vaccination with GM-CSF–producing B16 on
days 0, 3, and 6. The vaccinated mice were di-
vided over three groups that received the fol-
lowing Ab: CTLA-4 blocking Ab on days 0, 3,
and 6 (n   8,  ); depleting anti-CD25 Ab on
day  4 (n   8, ×); or depleting anti-CD25 Ab
on day  4 plus CTLA-4–blocking Ab on days
0, 3, and 6 (n   8,  ). (B) Survival data of mice
challenged subsutaneously (day 0) with 5   103
B16-BL6 tumor cells. Mice received either de-
pleting anti-CD25 Ab on day  4 (n   6,  ) or
were vaccinated on days 0, 3, and 6 with GM-
CSF–producing B16. The vaccinated mice
were divided over two groups that received the
following Ab: blocking anti–CTLA-4 Ab on days 0, 3, and 6 (n   9,  ); or depleting anti-CD25 Ab on day  4 combined with blocking anti-CTLA-4
Ab on days 0, 3, and 6 (n   9,  ). See Materials and Methods for details. Significant (A, P   0.025; B, P   0.0004, log rank test) differences were found
between B16-GM-CSF vaccinated mice that received either anti–CTLA-4 Ab ( ) or were injected with anti-CD25 Ab plus anti-CTLA-4 Ab ( ).
Representative results from two independent experiments are shown.
Figure 4. Depigmentation of mice vaccinated with GM-CSF–produc-
ing B16. Groups of mice were untreated (n   12,  ), treated with B16-
GM-CSF and anti–CTLA-4 Ab alone (n   16,  ) or in combination with
prior CD25 depletion (n   20,  ) as described in Material and Methods.
Each marker represents the average depigmentation score for a single
mouse from three independent (blinded) scorings. For each group the
mean is shown   SEM. Significant (P   0.02, Student’s t test) difference
was found between B16-GM-CSF vaccinated mice that received either
anti–CTLA-4 Ab alone ( ) or in combination with anti-CD25 Ab ( ).827 Sutmuller et al.
through CTLA-4 blockade and CD25 depletion can have
synergistic effects on antitumor and autoimmune CTL re-
sponses in B16-BL6–challenged mice. This suggests that
CD25  Treg cells still exert their function in the presence
of CTLA-4 blockade and, thereby, that immunomodula-
tion through CTLA-4 and the CD25  T cell subset can
constitute alternative regulatory mechanisms.
Enhanced TRP-2180–188–specific CTL Responses in the Ab-
sence of CD25  Treg Cells. Our experiments show a clear
correlation between efficacy of the antitumor response and
the extent of autoimmune depigmentation. Recent data
have revealed that both processes can be induced by spe-
cific vaccination against the melanocyte/melanoma differ-
entiation antigen TRP-2, either with a DNA-based vac-
cine encoding the entire antigen (31), or with dendritic
cells loaded with the H-2Kb–restricted CTL epitope TRP-
2180–188 (32). Since the therapeutic effect of the vaccination
in our experimental system was shown to depend on
CD8  T cells, we tested the level of CTL immunity against
the TRP-2180–188 epitope. Analysis of TRP-2180–188 specific
CTL response was performed by flow cytometry using Kb/
TRP-2180–188 tetramers on blood of tumor-challenged
mice. In vaccinated mice, numbers of tetramer  CD8  T
cells are clearly increased compared with background levels
detected in naive mice (Figs. 2, C and D, and 5 A, no. 1).
Also tumor-bearing mice receiving no treatment at all de-
velop an, albeit small, increase in the percentage of TRP-
2180–188–specific CD8  T cells. When tumor-bearing mice
were vaccinated using GM-CSF–producing vaccine and
CTLA-4 blockade, frequencies of TRP-2180–188–specific
CD8  T cells are considerably augmented compared with
nonvaccinated mice. Importantly, these frequencies are in-
creased most prominently (to  2% of the CD8  popula-
tion) if the treatment with GM-CSF–producing vaccine
and CTLA-4 blockade is performed in CD25-depleted an-
imals (Fig. 5 A, no. 4). This demonstrates directly that
CD25  T cells can inhibit the induction of an autoreactive
CTL response, even in the presence of CTLA-4 blockade,
and correlates with the in vivo tumor rejection data (Fig. 3,
A and B). Notably, these data also indicate that in CD25-
depleted mice, vaccine-induced TRP-2180–188–specific
CD8  T cell responses require CD4  T cell help (Fig. 5 A,
no. 6), since this response is absent in CD4-depleted mice
(see also below).
To analyze the functional activity of the TRP-2–specific
CTLs detected by tetramer staining, we measured, directly
ex vivo, intracellular IFN-  production in CD8  T cells
derived from vaccine draining lymph nodes in response to
TRP-2 peptide. Fig. 5 B shows that TRP-2–specific IFN- 
production can be detected in CD8  T cells from mice
that received the B16-GM-CSF vaccine in combination
with CD25 depletion and CTLA-4 blockade. In the ab-
sence of CD25 depletion or CTLA-4 blockade the num-
bers of IFN- –producing CTLs are decreased, similarly as
found for tetramer staining. As expected, the percentage of
specific CTLs was higher in the vaccine draining lymph
nodes than in the blood. We also analyzed IFN-  release
by splenocyte cultures in the presence of the TRP-2180–188
peptide (Fig. 6). The IFN-  release data showed that TRP-
2180–188–specific CTL immunity can be detected in spleno-
Figure 5. Analysis of TRP-
2180–188–specific CD8  T cells in
vaccinated mice. (A) Blood lym-
phocytes were stained on day 17
after tumor challenge for the
presence of TRP-2180–188–spe-
cific CD8  T cells using an
APC-conjugated TRP-2180–188
Kb-tetramer and anti–CD8-
FITC. The percentage of
TRP-2180–188–specific CD8  T
cells of total CD8  T cells is in-
dicated. Treatments of mice
were as follows: group 1, naive
mice; groups 2–8, B16-BL6 tu-
mor challenge on day 0; groups
3–7, vaccination on days 0, 3,
and 6 with GM-CSF–produc-
ing B16. If indicated, 200  g
blocking anti–CTLA-4 Ab was
injected on days 0, 3, and 6, de-
pleting anti-CD25 Ab (450  g)
was injected at day  4. Signifi-
cant difference (P   0.03, Stu-
dent’s t test) was found between
mice from groups 3 and 4. Error
bars indicate the SD of three
measurements from one experi-
ment. One representative exper-
iment of two is shown. (B) Lymph node cells were stained on day 17 after tumor challenge for the presence of TRP-2–specific IFN- –producing CD8 
T cells. Results indicate the percentage of TRP-2–specific CD8  T cells from the total CD8 population calculated as (percentage of TRP-2 respond-
ers)   (percentage of E1A responders). A representative result from two experiments is shown.828 Suppression of CTL Responses through CTLA-4 and Treg Cells
cyte cultures from mice that had received treatment with
GM-CSF–producing vaccine and CTLA-4 blockade and
that this activity is markedly increased in mice that had also
undergone CD25 depletion (Fig. 6, no. 4).
Administration of Anti-CD25 mAb Can Deplete Effector T
Cell Populations. It is well known that CD25, besides be-
ing a marker for Treg cells, is an activation marker on lym-
phocyte subsets (33, 34). The depletion of T cells express-
ing the CD25 marker may therefore not only eliminate
Treg cells but also deplete preexisting antigen-experienced
T cell populations of both CD4  and CD8  lineages. We
investigated the latter in an experimental setup in which
we established such preexisting populations by preventive
vaccination against B16-BL6 tumor challenge. Most mice
prevaccinated with B16-GM-CSF in combination with
CTLA-4 blockade exhibited tumor-specific memory in
that they were capable of rejecting a subsequent tumori-
genic dose of B16-BL6 (Fig. 7 A). CD4  T cell depletion
of immunized mice completely abrogated the protective
effect of the prophylactic vaccination. This absolute re-
quirement of CD4  T cells for protective vaccination is in
sharp contrast to our findings in the therapeutic setting
(Fig. 1), where CD4  T cell depletion even enhances the
efficacy of treatment. Our observations are in line with
those of Hung et al. (35), who reported a key role for
CD4  T cells in the vaccination-induced immune response
against B16. Importantly, also CD25  T cell depletion 4 d
before tumor challenge, a timing also applied in our thera-
peutic experiments, negatively affected the capacity of pre-
vaccinated mice to reject B16-BL6. This supports the no-
tion that CD25 depletion can result in the elimination of
protective antigen-experienced T cells that were elicited by
the vaccine. Since the negative effect of CD25 depletion is
less profound than CD4 depletion, it is likely that T cell
help provided by CD4  T cells, that are CD25  at the time
of challenge, also plays an important role in the immune
defense against B16-BL6.
In view of the fact that depletion of the CD25  T cell
subset can indeed result in the elimination of cells that are
positively involved in B16 tumor eradication, we reevalu-
ated the importance of the CD4  and CD8  T cell subsets
in antitumor therapy involving CD25 depletion. We have
previously shown that rejection of B16-BL6 after therapeu-
tic vaccination with GM-CSF–producing B16 in combina-
tion with CTLA-4 blockade is highly dependent on the
CD8  T cell subset, but not on CD4  T cells (see Fig. 1
and reference 18). We now demonstrate that in CD25-
depleted mice full efficacy of this therapy does not only de-
Figure 6. IFN-  release in response to TRP-2180–188 peptide. Spleno-
cytes from mice were in vitro restimulated with irradiated B16/B7.1 and
tested for recognition of TRP-2180–188 peptide-loaded target cells in an
IFN-  release assay 1 wk later. Treatments of mice are described in leg-
end to Fig. 5. Values indicate average from three measurements with SD
indicated. One representative experiment of two is shown.
Figure 7. Analysis of in vivo anti-CD25 mAb administra-
tion. (A) Prophylactic vaccination efficiency is decreased by
administration of anti-CD4 mAb or anti-CD25 mAb. Mice
received either no treatment (n   6,  ) or were vaccinated
with B16-GM-CSF and blocking anti-CTLA-4 Ab on days
0, 3, and 6. The vaccinated mice were divided over three
groups that received the following Ab in combination with
CD4 depletion (n   8, ×), CD25 depletion (n   8,  ), or
without depletion (n   8,  ). Administration of depleting
mAb was performed on day 17. All mice were challenged
with 5   103 B16-BL6 tumor cells on day 21. (B) Thera-
peutic vaccination in CD25-depleted mice is dependent of
CD4  as well as CD8  T cells. Therapeutic treatment with
irradiated GM-CSF–producing B16 cells plus CTLA-4
blockade was performed in mice depleted for CD25  T cells
(n   8,  ), in mice depleted for CD25  T cells and CD8 
T cells (n   8,  ), or in mice depleted for CD25  T cells
and CD4  T cells (n   8,  ). Significant (P   0.025, log
rank test) difference was found between CD25 depleted/
vaccinated mice ( ) and CD4 plus CD25 depleted/vacci-
nated mice ( ).829 Sutmuller et al.
pend on the action of CD8  T cells, but also on the avail-
ability of help by CD4 CD25  T cells (Fig. 7 B). This
result is mirrored by our observation that the number of
tetramer-positive CTLs in mice receiving this treatment is
decimated if these mice in addition were depleted of their
CD4  T cells (Fig. 5 A, no. 6). It is likely that also a sub-
population of CD4  T cells positively affects the antitumor
response in mice that receive antitumor treatment without
CD25 depletion. However, in this setting the inhibitory
effect of CD4 CD25  Treg cells outweighs the beneficial
effect of the CD4 CD25  Th cells.
CTLA-4 Blockade Enhances CTL Induction In Vitro and In
Vivo. The synergistic effect of CTLA-4 blockade and
CD25 depletion on CTL induction and antitumor response
described here could in theory still be caused by differences
in biokinetics of the two antibodies used. To prove that
CTLA-4 blockade and Treg cell function are indeed alter-
native pathways for regulation of autoreactive CTL re-
sponses, we separated the anti–CTLA-4 and anti-CD25
antibody treatments in space and time and analyzed the ef-
fects with regard to CTL induction in vitro as well as in
vivo. For this purpose we used CD25-depleted spleno-
cytes. CD25 depletion was accomplished by injection of
450  g of anti-CD25 antibody on 2 d consecutively and
harvesting the splenocytes 3 d later. Flow cytometry analy-
sis with noncrossreactive anti-CD25 (7D4) confirmed
 95% depletion of CD25  T cells. The CD25  spleno-
cytes were then used in an in vitro priming assay to induce
in vitro TRP-2180–188–specific CTLs. Fig. 8 A shows that
CD25  splenocytes stimulated with TRP-2180–188 peptide
and cultured for 1 wk specifically recognize TRP-2180–188–
loaded target cells. CTLA-4 blockade during the first 3 d of
culturing markedly increased the induction of the TRP-
2180–188–specific response. We also used 5   107 CD25 
splenocytes to reconstitute T cell–deficient C57BL/6 Nude
(nu/nu) recipients. The nude recipients were subsequently
vaccinated with GM-CSF–producing B16 with or without
CTLA-4–blocking antibodies. 3 wk after the last vaccina-
tion, the spleens were harvested and the splenocyte cultures
were analyzed for the presence of TRP-2180–188–specific
CTLs. In T cell cultures from recipients reconstituted with
complete splenocytes and vaccinated with or without
CTLA-4 blockade no TRP-2180–188–specific reactivity was
demonstrable (Fig. 8 B). This is probably due to the de-
creased T cell numbers in reconstituted nude recipients
compared with normal C57BL/6 mice rendering it more
difficult to initiate a detectable CTL response. However,
when nude mice were reconstituted with CD25  spleno-
cytes, specific IFN-  release in response to TRP-2180–188
was detected, but only if the GM-CSF–producing B16
vaccine was combined with CTLA-4 blockade. These in
vitro and in vivo results show that CTLA-4 blockade acts
in the complete absence of CD25  T cells, probably by di-
rectly releasing the brakes on costimulation in responding
T cells, including effector CTLs.
Discussion
The combined results show that the efficacy of therapeu-
tic vaccination against experimental melanoma is markedly
increased by interfering with mechanisms that normally
keep autoimmune responses in check. Antitumor treatment
is strongly improved if vaccination is either accompanied
by CTLA-4 blockade or preceded by a depletion of
CD25  Treg cells. These intervention strategies act syner-
gistically, in that combination of CTLA-4 blockade and
Figure 8. CTLA-4 blockade en-
hances CTL induction in the ab-
sence of CD25  Treg cells. CD25 
splenocytes were used to analyze the
effect of CTLA-4 blockade on the
induction of effector CTL in vitro
(A) and in vivo  (B). (A) Naive
CD25   splenocytes were, if indi-
cated, stimulated with TRP-2 pep-
tide loaded target cells and anti–
CTLA-4 (50 µg/ml) during the first
3 d of culture. At day 7, specific
IFN-  release in response to TRP-2
peptide was measured. (B) C57BL/6
nude recipients were reconstituted
with 5   107 splenocytes from wild-
type C57BL/6 mice on day 0 and
vaccinated with GM-CSF–produc-
ing B16 cells on days 4, 7, and 10. If
indicated, CD25  splenocytes were
used to reconstitute the recipients
and 200 µg of CTLA-4–blocking
Ab was administered on days 4, 7,
and 10. 3 wk after the last vaccina-
tion splenocytes from mice were in
vitro restimulated with irradiated B16/B7.1 and tested for recognition of TRP-2180–188 peptide-loaded target cells in an IFN-  release assay 1 wk later.
Values indicate average from three measurements with SD indicated. Representative results from two independent experiments are shown. Significant
difference (A, P   0.03; B, P   0.01, Student’s t test) was found between treatments no. 3 and 4.830 Suppression of CTL Responses through CTLA-4 and Treg Cells
depletion of CD25  Treg cells results in maximal efficacy
of therapeutic vaccination. The potency of the different
treatment modalities for preventing B16 melanoma out-
growth strongly correlates with the extent of autoimmune
skin depigmentation in the treated mice as well as with the
frequency of TRP-2180–188–specific CTLs detected in the
periphery. Furthermore, antitumor protection was abro-
gated upon depletion of the CD8  T cell subset. There-
fore, our data indicate that the CTL response against mela-
noma-associated autoantigens is an important component
of the therapeutic antitumor immune response, and that
this response can be enhanced through interference with
immunoregulatory mechanisms. The synergism in the ef-
fects of CTLA-4 blockade and depletion of CD25  Treg
cells suggest that these intervention strategies act on differ-
ent regulatory pathways. Indeed, in the complete absence
of CD25  Treg cells, CTLA-4 blockade markedly aug-
ments the CTL response in vitro and in vivo, clearly sup-
porting independent and synergistic activities.
Although the role of CD25  Treg cells in the suppres-
sion of autoimmune responses is by now generally ac-
knowledged, the mechanism by which these cells exert
their regulatory effects is still a matter of debate. In particu-
lar, it has recently been proposed that CTLA-4 would play
an essential role in Treg cell function. This was, amongst
others, suggested by the observation by two laboratories
that CTLA-4 is constitutively expressed by CD4 CD25 
Treg cells, but not or to a much lower extent by other
CD4  T cell subsets (36, 37). Analysis was performed on
permeabilized cells, allowing detection of both membrane
and cytoplasmic localized CTLA-4. Therefore, although
these data do not directly assess whether CD25  Treg cells
constitutively display functional CTLA-4 at their surface, it
is clear that in these T cells intracellular supplies of this im-
munoregulatory molecule are readily available for mobili-
zation to the membrane. The functional importance of the
CTLA-4 regulatory signal was demonstrated in a murine
model for CD4  T cell–induced colitis by the fact that the
capacity of CD25  Treg cells to inhibit the pathogenic
CD4  cells was abolished by administration of CTLA-4–
blocking Ab (36). However, as acknowledged by the au-
thors, these experiments do not rule out the possibility that
CTLA-4 blockade has a direct effect on the pathogenic T
cells. In the second study, it is demonstrated that CTLA-4
is critically involved in the suppressive action of CD25 
Treg cells in vitro (37). Further experiments showed that
repeated administration of high doses of anti–CTLA-4 Ab
induced autoimmune disease in normal Balb/c mice,
whereas lower doses of this Ab failed to do so unless com-
bined with high doses of depleting anti-CD25 mAb. Ad-
ministration of anti-CD25 Ab alone did not induce overt
signs of autoimmune disease. Since this treatment results in
a strong reduction, but not in a complete elimination of
CD4 CD25  cells, the data were interpreted as showing
that CTLA-4 blockade on the remaining CD25  Treg cells
with low dose anti–CTLA-4 Ab suffices to eliminate the
remaining suppressive action by these cells. Importantly,
these in vivo experiments, similar to those published by
Reed and coworkers (36), do not exclude a direct effect of
CTLA-4 blockade on the pathogenic effector T cells.
Taken together, the available data argue that CTLA-4 is
likely to contribute to the action of CD25  Treg cells, but
there is ample evidence that this immunoregulatory mole-
cule also has a direct suppressive effect on the responder T
cell population (6, 8, 38). Moreover, the current study
shows that CTLA-4 blockade in the absence of CD25 
Treg cells has a direct effect on the in vitro and in vivo in-
duction of autoreactive effector CTLs (Fig. 8). Accord-
ingly, intervention with immune regulatory mechanisms
through both CTLA-4 blockade and elimination of
CD25  Treg cells can result in more profound induction
of autoimmune responses than intervention with only one
of these mechanisms (Fig. 3).
CD25 is not exclusively expressed by CD4  Treg cells,
but also by antigen-experienced T cells. In particular, acti-
vated effector T cells of both CD4  and CD8  lineages
can be positive for this surface marker (33). This explains
why treatment of prevaccinated mice with anti-CD25 Ab
diminished the protective antitumor effect of the vaccina-
tion (Fig. 7 A) and underscores the importance of proper
timing when applying in vivo depletion of CD25  T cells
in combination with vaccination for the immunotherapy
of cancer. Even though administration of depleting anti-
CD25 Ab greatly enhances the efficacy of antitumor ther-
apy involving vaccination and CTLA-4 blockade, also in
this case it results in loss of a valuable T cell subset. This
loss is indicated by the fact that the efficacy of antitumor
treatment by vaccination and CTLA-4 blockade does not
depend on CD4  T cell help, whereas in CD25-depleted
mice additional loss of CD4  T cell help markedly reduces
the efficacy of the therapy (Fig. 7 B) as well as the magni-
tude of the TRP-2180–188–specific CTL response (Fig. 5
A). Possibly, the CD8  T cell population in normal mice
harbors a CD25  subset that is activated upon therapeutic
vaccination in combination with CTLA-4 blockade, but
that is eliminated when mice are treated with anti-CD25
Ab before vaccination. Our observations in this murine
melanoma model are reminiscent of recent reports that de-
scribe the presence of circulating melanoma/melanocyte
antigen-specific CTLs in the blood of healthy human be-
ings, although it should be noted that these latter CTLs
appeared to have a naive rather than an antigen-experi-
enced phenotype (39, 40). We hypothesize that such pre-
existing CD8  CTLs, which may be naive or antigen ex-
perienced, are kept in check by CTLA-4– and CD25 
Treg-dependent mechanisms and that it is the activity of
these CTL that is unleashed upon blockade of these im-
munoregulatory mechanisms.
In conclusion, the data presented in this paper reveal that
combination of CTLA-4 blockade and elimination of
CD25  Treg cells can result in more effective autoreactive
and therapeutic antitumor immunity than when these in-
tervention strategies are applied separately. Our findings
support the notion that CD25  Treg cells and CTLA-4
represent two alternative pathways for suppression of au-
toreactive T cell immunity, but do not exclude that func-831 Sutmuller et al.
tional overlap between these pathways exists. Notwith-
standing this possible overlap, simultaneous intervention
with both regulatory mechanisms appears to be a highly
promising strategy for the induction of T cell immunity
against tumor-associated autoantigens in the immunother-
apy of cancer.
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